Allergy Therapeutics Plc is a biotechnology company, which engages in the Research and Development of allergy treatments. The company is headquartered in Worthing, West Sussex and currently employs 584 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. The company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. The company sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.
Mr. Manuel Llobet es el Chief Executive Officer de Allergy Therapeutics PLC, se unió a la empresa desde 2009.
¿Qué tal es el rendimiento del precio de la acción ALLERGY THERAPEUTICS?
El precio actual de ALLERGY THERAPEUTICS es de $0.11, ha disminuido un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Allergy Therapeutics PLC?
Allergy Therapeutics PLC pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Allergy Therapeutics PLC?
La capitalización bursátil actual de Allergy Therapeutics PLC es $696.5M
¿Es Allergy Therapeutics PLC una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 3 analistas han realizado calificaciones de análisis para Allergy Therapeutics PLC, incluyendo 3 fuerte compra, 5 compra, 2 mantener, 0 venta, y 3 fuerte venta